# US 2014/0155322 A1 · Method of Preventing Or Reducing Scarring Of Human Skin > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155322 A1 - Document ID: US20140155322A1 - Status: Published application - Kind: A1 - Application number: 14/025,809 - Filed: 2013-09-12 - Published: 2014-06-05 - Earliest claimed: 2000-11-29 - Assignees: Pharmecosse Ltd. - Inventors: Claire Linge; Ian Paul Mackie - Web page: https://patentgrep.com/patent/US20140155322A1 ## CPC - A61K 38/28: Insulins - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the PPAR agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces/prevents scarring whilst enhancing re-epithelialisation of the wound and thus provides a dual action wound healing treatment. The present invention accordingly provides a highly effective prophylactic treatment for any individual suffering tissue trauma to reduce and/or prevent normal and/or pathological scarring. ## Claims ### Claim 1 A method of reducing dermal scarring in a skin wound of a human, which comprises administering to the skin wound, in a period consisting of up to about 2 days after the wound is formed and before a peak myofibroblast level is reached in the wound, an effective amount of an active agent selected from insulin and a specific peroxisome proliferator-activated receptor gamma (PPARγ) agonist. ### Claim 2 (depends on 1) A method according to claim 1, wherein the active agent is administered in a medicament for a dual action wound treatment comprising reducing or preventing scarring whilst accelerating or promoting wound healing. ### Claim 3 (depends on 1) A method according to claim 1, wherein the scarring is selected from scarring of human skin wounded as a result of burns, scalds, grazes, abrasions, incisional wounds, surgery and pathological skin scarring conditions. ### Claim 4 (depends on 1) A method according to claim 1, wherein the scarring is selected from fibrotic dermal scarring, hypertrophic scarring, and keloid scarring. ### Claim 5 (depends on 1) A method according to claim 1, wherein the active agent is administered as a topical composition or an injectable composition. ### Claim 6 (depends on 1) A method according to claim 1, wherein the active agent is administered to a skin wound or its vicinity, after the wound has been formed. ### Claim 7 (depends on 1) A method according to claim 1, wherein the active agent is insulin and is administered in a composition comprising a delivery vehicle, insulin in an amount from 50 picograms (1.25×10−6 IU) to 1000 micrograms (25 IU) per millilitre of the composition, and optional additional ingredients of the composition. ### Claim 8 (depends on 1) A method according to claim 1, wherein the active agent is a specific PPARγ agonist selected from: glitazones (thiazolidinediones), isoxazolidinediones, α-alkoxy-β-phenylpropanoic acids, fibrates, ureidofibrates, tyrosine-based PPARγ agonists, 2,3-disubstituted indole-5-acetic acid derivatives, phenylacetic acid derivatives, leukotriene antagonists, polyunsaturated fatty acids, eicosanoids, and derivatives and metabolites of prostaglandins. ### Claim 9 (depends on 1) A method according to claim 1, wherein the active agent is a specific PPARγ agonist selected from ciglitazone, troglitazone, pioglitazone, rosiglitazone, GW0207, GW1929, linoleic acid, linolenic acid, arachidonic acid, EPA, 9-HODE, 13-HODE, 15-HETE, 15-deoxy-Δ12, 14-prostaglandin J2, and any physiologically acceptable salt thereof. ### Claim 10 (depends on 1) A method according to claim 1, wherein the active agent is a specific PPARγ agonist and is administered in a composition comprising a delivery vehicle, the specific PPARγ agonist in a concentration between 40 picomolar to 50 millimolar, and optional additional ingredients of the composition. ### Claim 11 A method of reducing dermal scarring in the healed skin of a human after formation of a wound while maintaining a breaking strength of the healed skin substantially corresponding to that of healed skin which includes natural levels of scar tissue, which method comprises administering to the skin, in a period consisting of up to about 2 days after the wound is formed and before a peak myofibroblast level is reached in the wound, an effective amount of an active agent selected from insulin and a specific peroxisome proliferator-activated receptor gamma (PPARγ) agonist. ### Claim 12 (depends on 1) A method according to claim 1, wherein the active agent comprises a specific PPARγ agonist. ### Claim 13 (depends on 12) A method according to claim 12, wherein the active agent includes insulin. ### Claim 14 (depends on 13) A method according to claim 13, wherein the active agent includes one or more other active agents known for wound care uses. ### Claim 15 (depends on 12) A method according to claim 12, wherein the active agent includes one or more other active agents known for wound care uses. ### Claim 16 (depends on 1) A method according to claim 1, wherein the active agent comprises insulin. ### Claim 17 (depends on 16) A method according to claim 16, wherein the active agent includes one or more other active agents known for wound care uses.